publication date: Jul. 18, 2014
The American Association of University Professors has authorized a formal investigation of MD Anderson Cancer Center, a move that could result in censure.
The investigation was triggered by refusal on the part of MD Anderson’s administration to provide justification for denying tenure renewals to two faculty members.
The faculty members in question—Kapil Mehta and Zhengxin Wang—received unanimous votes in favor of renewal from the Faculty Senate Promotions & Tenure Committee, but the institution’s president, Ronald DePinho, ultimately decided not to extend their tenure.
|Memorial Sloan Kettering Seizes Top Cancer Hospital Prize from MD Anderson in U.S. News & World Report Rankings|
MD Anderson Cancer Center’s uninterrupted seven-year stretch as the top cancer hospital in the U.S. News & World Report rankings has come to an end.
Memorial Sloan Kettering Cancer Center has broken the spell of being the perpetual runner-up and moved to the lead.
The result is as close as cancer care can come to a photo finish:
• MSKCC: 100 percent.
• MD Anderson: 99.9 percent.
|Capitol Hill |
Advocates Lobby Congress To Close Medicare Loophole For Colonoscopy Coverage
A coalition of advocacy groups focused on colorectal cancer asked Congress to fix the loophole in Medicare coverage of colonoscopies.
The group, organized by Fight CRC and the American Cancer Society Cancer Action Network, met July 16 to lobby for proposed legislation that would ensure cost is not a barrier to colon cancer screenings.
University of Arizona forms plan with Banner Health to build statewide health system
Roswell Park Cancer Institute granted approval for genome trials by New York State Department of Health
Medical College of Wisconsin receives $2.6 million grant from NCI
Dana-Farber Cancer Institute forms three-year immuno-oncology lung cancer collaboration with Johnson & Johnson and Janssen Biotech
Eli Lilly and Company and Immunocore Limited form collaboration
The Ohio State University and the University of Michigan sign agreement with Venture Therapeutics Inc.